iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
MWN-AI** Summary
iBio, Inc. (NASDAQ: IBIO), an innovator in developing therapies for obesity and related diseases, announced promising preclinical data regarding its novel treatment, IBIO-610, an Activin E antibody candidate. The data, obtained from a study involving obese non-human primates (NHPs), revealed that IBIO-610 effectively reduces fat mass while sparing lean muscle. In the study, after two administration cycles every eight weeks, a noticeable reduction was observed: visceral fat decreased by 6.7% and total fat mass by 5.2%. Importantly, there was only a minimal increase in lean mass, highlighting the fat-selective action of the therapy.
The results align with previously documented effects in rodent studies and human trials focused on the Activin E pathway, suggesting consistent outcomes across different models. IBIO-610's half-life of approximately 33.2 days in NHPs, with projections indicating up to 100 days in humans, points to the potential for convenient dosing schedules, potentially allowing for treatment just twice a year.
Dr. Martin Brenner, CEO and Chief Scientific Officer of iBio, emphasized the significance of these findings, underscoring the treatment's potential to improve patient outcomes by specifically targeting fat loss while preserving lean muscle. iBio plans to present the full dataset, including additional biomarkers, at various scientific conferences throughout 2026.
The company continues to harness its AI-driven discovery platform to support the development of next-generation biopharmaceuticals aimed at addressing significant unmet medical needs in obesity and cardiometabolic conditions. However, potential investors should note the inherent uncertainties and risks involved in the drug development process, as outlined in their filings with the SEC.
MWN-AI** Analysis
iBio, Inc. (NASDAQ: IBIO), a promising player in the biotechnology sector focusing on obesity and cardiometabolic diseases, recently reported preclinical data that suggests its potential treatment, IBIO-610, might be the key to fat-selective weight loss. This discovery arises from a study on obese non-human primates, where IBIO-610 was associated with a notable reduction in visceral fat and total fat mass, while maintaining lean mass. Given the increasing global prevalence of obesity and its associated health risks, iBio's advancements may put it ahead in the race for innovative therapies.
For investors, this development is significant as it underscores iBio's unique position in targeting the Activin E pathway—indicating a differentiated mechanism of action that may translate effectively into human clinical settings. The promising results from animal studies could lead to positive investor sentiment, especially if pivotal clinical trials yield similar outcomes. Additionally, the potentially extended half-life of IBIO-610, projecting up to 100 days in humans, suggests a convenient dosing regimen that is highly appealing in a market where compliance can often impact therapeutic success.
However, caution is warranted. The reported data stem from a small, non-statistically powered study, which raises the possibility that further testing may not achieve the anticipated results. Furthermore, regulatory hurdles remain a critical factor in the biotechnology space. Investors should keep a keen eye on subsequent developments, including the complete dataset presentation and any forthcoming clinical trial results.
In conclusion, while iBio's recent findings provide a valuable opportunity for growth, market participants should remain vigilant, monitoring further developments while considering both the innovative potential and inherent risks associated with the biopharmaceutical sector. This balanced approach will be critical for navigating investment decisions related to iBio and its pipeline candidates.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate.
The preclinical body composition data demonstrates IBIO-610 reduced fat mass in obese NHPs compared to vehicle-treated obese NHPs, in a small, not statistically powered study. Following two once-every-eight-week dosing, IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2%, with only a slight up-tick in lean mass following treatment. This fat-selective profile in our NHP study is consistent with the effects we previously observed in rodents and with body composition outcomes reported by other companies in human clinical trials targeting the Activin E pathway. These data support continued evaluation of IBIO-610’s potential as a differentiated therapy in obesity, cardiometabolic and cardiopulmonary diseases.
“These data reinforce IBIO-610’s potential to deliver fat-selective improvements in body composition while maintaining lean mass,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “When added to the previously demonstrated extended half-life, these results further confirm the potential of IBIO-610 as a first-in-class therapy, and the capability of our AI-enabled discovery platform to address complex targets obesity, cardiometabolic and cardiopulmonary diseases, and may significantly improve the lives of patients.”
Previously reported data from the study demonstrated IBIO-610’s extended 33.2-day half-life in obese NHPs and a projected human half-life of up to 100 days, supporting the potential for convenient, twice-yearly dosing. The complete dataset, which will include analysis of additional biomarkers, will be presented by iBio at scientific conferences throughout 2026.
“These findings are consistent with body composition effects reported for therapies targeting the Activin E pathway, including human siRNA approaches,” said Cory Schwartz, Ph.D., Director of Research and Early Development at iBio. “We believe IBIO-610’s fat-selective biology supports its potential to drive targeted fat loss while maintaining lean mass. Our team is continuing its thorough analyses of the dataset spanning metabolic, biomarker, and mechanistic endpoints, and we look forward to presenting additional insights.”
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity; the capability of iBio’s AI-enabled discovery platform to address complex targets in cardiometabolic, obesity and cardiopulmonary diseases and significantly improve the lives of patients; the presentation by iBio of the complete dataset, which will include analysis of additional biomarkers, at scientific conferences throughout 2026; the potential of IBIO-610’s fat-selective biology to drive targeted fat loss while maintaining lean mass; iBio’s ability to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases and other hard-to-treat diseases; iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Activin E to be a successful target for cardiometabolic disorders and obesity and iBio’s antibody to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; iBio’s ability to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases and other hard-to-treat diseases; iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the Securities and Exchange Commission (the “SEC”) including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ**
What key milestones should investors expect from iBio Inc. (NASDAQ: IBIO) regarding the further development and potential commercialization of IBIO-6following the promising preclinical data?
2. How does iBio Inc. (IBIO) plan to mitigate the risks mentioned in their forward-looking statements related to the Activin E antibody and its application in cardiometabolic diseases?
3. In what ways does iBio Inc. (IBIO) anticipate leveraging its AI-enabled discovery platform to accelerate the development of therapies like IBIO-610 for obesity and cardiopulmonary diseases?
4. What are the anticipated next steps for iBio Inc. (NASDAQ: IBIO) in presenting their complete dataset on IBIO-610, and how will that impact investor confidence in the company's future prospects?
**MWN-AI FAQ is based on asking OpenAI questions about iBio Inc. (NYSE: IBIO).
NASDAQ: IBIO
IBIO Trading
2.06% G/L:
$6.41 Last:
2,193,602 Volume:
$5.71 Open:
